Superworth

Travere Therapeutics price to sales ratio TVTX

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026
8.0×
10-year median
5.9×
Against its 10-year history
92nd
percentile: 0 is its lowest day, 100 its highest
10-year range
2.0× to 10.5×
Peer median
5.8×

Travere Therapeutics' price to sales ratio is 8.0× as of Oct 23, 2026.

That is above its ten-year median of 5.9×, higher than on 92% of days in the last ten years.

Over that time it ranged from 2.0× in Nov 2023 to 10.5× in Sep 2026.

The median for 10 large drugmakers of a similar size is 5.8×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far8.0×5.0×10.5×
20258.1×4.5×8.8×
20246.6×2.8×7.7×
20233.2×2.0×6.9×
20226.3×5.6×8.2×
20218.6×4.0×8.7×
20207.2×2.7×7.3×
20193.6×2.8×6.0×
20185.7×5.4×7.9×
20175.5×4.6×6.7×
20165.6×4.6×7.8×
20158.3×8.1×27.6×

Against its peers

Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
TVTXTravere Therapeutics8.0×
INDVIndivior Pharmaceuticals3.1×
ARQTArcutis Biotherapeutics8.5×
LQDALiquidia8.5×
KNSAKiniksa Pharmaceuticals International7.1×
LGNDLigand Pharmaceuticals20.8×
OGNOrganon0.6×
AMRXAmneal Pharmaceuticals2.1×
ALKSAlkermes plc.4.4×
NRIXNurix Therapeutics3.9×
TGTXTG Therapeutics10.4×
Peer median5.8×

Where Travere Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Travere Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.